The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Lymphoma Research Foundation gives $3.5M in grants to 28 researchers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Lymphoma Research Foundation has awarded 28 new research grants in 2024, amounting to $3.5 million to cancer researchers who will advance understanding of lymphoma and lay the foundation for improved patient care.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic

“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.
By Paul Goldberg and Katie Goldberg
Clinical Roundup

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account